Key result
Atrial fibrillation is associated with an increased risk of cognitive impairment and dementia, with potential protective effects from atrial fibrillation therapy requiring further randomized trials.
Why the study?
Does atrial fibrillation therapy prevent cognitive impairment and dementia in patients with atrial fibrillation?
Does atrial fibrillation therapy prevent cognitive impairment and dementia in patients with atrial fibrillation?
Highlights the potential protective role of atrial fibrillation therapies against cognitive impairment and dementia, calling for future randomized trials to clarify these links.
Atrial fibrillation is associated with an increased risk of cognitive impairment and dementia. The mechanisms are not well known, but they are probably multifactorial and involve atrial myopathy, cardio-embolism, cerebral hypoperfusion, and comorbidities (systemic vascular sclerosis, disease of the small cerebral vessels, inflammation, etc.). Atrial fibrillation therapy could have a protective effect on dementia through diversified actions: (i) prevention of left atrial remodelling; (ii) prevention of cardio-embolism and silent (and not) cerebral infarcts; (iii) improvement of cardiac output and cerebral perfusion. Randomized trials will be needed to clarify the links between left atrium and dementia and to identify the most appropriate therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Pierfranco Terrosu (2022) conducted a review in Atrial fibrillation and dementia. Atrial fibrillation therapy was evaluated. Atrial fibrillation is associated with an increased risk of cognitive impairment and dementia, with potential protective effects from atrial fibrillation therapy requiring further randomized trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: